milatuzumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
GVHD (Acute or Chronic)
Conditions
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Trial Timeline
Dec 1, 2013 → Mar 1, 2015
NCT ID
NCT01663766About milatuzumab
milatuzumab is a phase 1 stage product being developed by Gilead Sciences for GVHD (Acute or Chronic). The current trial status is terminated. This product is registered under clinical trial identifier NCT01663766. Target conditions include GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01663766 | Phase 1 | Terminated |
| NCT00868478 | Phase 1/2 | UNKNOWN |
| NCT00603668 | Phase 1/2 | Completed |
| NCT00421525 | Phase 1/2 | Completed |
Competing Products
19 competing products in GVHD (Acute or Chronic)